J&J settles by paying $50M to Emergent for their violation of FDA regulations in manufacturing J&J covid vaccine.
You read it correctly.
On July 2, 2020, J&J (Janssen), then part of the Operation Warp Speed, entered into an agreement with Emergent BioSolutions for the manufacture of its viral vector-based COVID-19 vaccine.
However, Emergent was fou…
Keep reading with a 7-day free trial
Subscribe to Due Diligence and Art to keep reading this post and get 7 days of free access to the full post archives.